FRM
PTGX icon

Fox Run Management’s Protagonist Therapeutics PTGX Stock Holding History

Fox Run Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,654
Closed -$581K – 1176
2025
Q4 		$581K Buy
6,654
+3,551
+114% +$291K 0.09% 431
2025
Q3 		$206K Buy
+3,103
New +$176K 0.03% 796
2024
Q1 		– Sell
-31,275
Closed -$717K – 1004
2023
Q4 		$717K Buy
+31,275
New +$547K 0.18% 177
2023
Q3 		– Sell
-27,931
Closed -$771K – 936
2023
Q2 		$771K Buy
+27,931
New +$699K 0.22% 149
2023
Q1 		– Sell
-28,970
Closed -$316K – 881
2022
Q4 		$316K Sell
28,970
-11,713
-29% -$98.8K 0.13% 324
2022
Q3 		$343K Buy
+40,683
New +$385K 0.13% 306

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Fox Run Management's PTGX Position: Q1 2026 in Review

Fox Run Management sold out of Protagonist Therapeutics (PTGX) in Q1 2026, closing a stake of 6,654 shares — an estimated $581K sold.

Fox Run Management first reported a position in PTGX in Q3 2022 and held it in 6 quarters. The position peaked at $771K in Q2 2023. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Fox Run Management reported no remaining Protagonist Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Fox Run Management sold 6,654 Protagonist Therapeutics shares in Q1 2026, an estimated $581K.
  • Fox Run Management first reported a position in Protagonist Therapeutics in Q3 2022 and held it in 6 quarters.
  • Fox Run Management's Protagonist Therapeutics position peaked at $771K in Q2 2023.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Fox Run Management's 13F filing for Q1 2026, filed 12 May 2026.